Evidence map›Paper›PMID 34112481›Full record

ArticleThe journal of allergy and clinical immunology. In practice2021

Reply to "How important is the second dose of the COVID-19 mRNA vaccine?"

Marcus S Shaker, Elizabeth Phillips, Kimberly G Blumenthal, Elissa M Abrams, Aleena Banerji, John Oppenheimer, Timothy K Vander Leek, Douglas P Mack, Paige G Wickner, Alexander G Singer and 2 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Marcus S ShakerDartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, NH; Geisel School of Medicine at Dartmouth, Hanover, NH. Electronic address: Marcus.S.Shaker@Dartmouth.edu.
Elizabeth PhillipsDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Kimberly G BlumenthalDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston, Mass.
Elissa M AbramsDepartment of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, MB, Canada.
Aleena BanerjiDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass.
John OppenheimerRutgers New Jersey Medical School, Newark, NJ.
Timothy K Vander LeekPediatric Allergy and Asthma, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.
Douglas P MackMcMaster University, Hamilton, ON, Canada; Halton Pediatric Allergy, Burlington, ON, Canada.
Paige G WicknerHarvard Medical School, Boston, Mass; Division of Allergy and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Alexander G SingerDepartment of Family Medicine, University of Manitoba, Winnipeg, MB, Canada.
David A KhanDivision of Allergy & Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Matthew GreenhawtDepartment of Pediatrics, Section of Allergy and Immunology, Children's Hospital Colorado, University of Colorado Denver School of Medicine, Denver, Colo.

Funding

NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C. · 2015 to 2019
$13.0M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysisR21AI139021 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2019
$435k
NHGRI NIH HHS R01 HG010863NIAID NIH HHS R01 AI152183NIAID NIH HHS R21 AI139021NIAID NIH HHS U01 AI154659NIGMS NIH HHS P50 GM115305
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesHumansRNA, MessengerSARS-CoV-2COVID-19 VaccinesRNA, Messenger

Identifiers

PMID34112481
PMCPMC8181594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.